08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

ABT-806: Phase I started

Abbott began a 6-month, open-label, dose-ranging Phase I trial to evaluate IV ABT-806 in up to 30 patients. Abbott has rights to the compound from Life Science under a 2008 deal (see BioCentury, Nov. 24,...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Company News

Life Science Pharmaceuticals, Abbott deal

Life Science granted Abbott exclusive, worldwide rights to develop and commercialize ch806 to treat cancer and other indications, including psoriasis. Abbott did not disclose its plans for the chimeric antibody targeting a tumor-specific epitope...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Clinical News

Ch806: Phase I data

In a dose-escalation, Australian Phase I trial in 8 cancer patients, ch806 showed tumor-specific targeting with no evidence of normal tissue uptake and no significant toxicity. Doses of up to 40 mg/m 2 were well...